已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 916: Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC)

表观遗传学 DNA甲基化 结直肠癌 肿瘤科 阶段(地层学) 甲基化 种系突变 CpG站点 分析灵敏度 内科学 癌症研究 医学 胎儿游离DNA 癌症 生物 DNA 病理 遗传学 突变 基因 基因表达 怀孕 古生物学 胎儿 替代医学 产前诊断
作者
Seung-Tae Kim,Victoria M. Raymond,Joon Oh Park,Elena Zotenko,Young Suk Park,Matthew Schultz,Won Ki Kang,Oscar Westesson,Hee-Cheol Kim,Yupeng He,Justin I. Odegaard,Stefanie Mortimer,William J. Greenleaf,Ariel Jaimovich,Jeeyun Lee,AmirAli Talasaz
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:79 (13_Supplement): 916-916 被引量:17
标识
DOI:10.1158/1538-7445.am2019-916
摘要

Abstract Background: ctDNA has the potential to identify patients (pts) with early stage cancer; however, current assays are challenged by limited sensitivity (~50%), reliance on a single analyte (e.g. somatic mutation detection), and/or the need for tumor tissue or genomic DNA sequencing to interpret ctDNA results. Recent studies have demonstrated that ctDNA can be detected using other biomarkers including DNA methylation. We developed a technology in which both somatic mutations and epigenomic alterations can be analyzed in a single assay. Methods: Using a large database of cell-free DNA (cfDNA) profiles generated from advanced cancer patients, we designed a targeted sequencing assay that detects somatic variants, methylation alterations, and other epigenomic variations at transcription factor binding sites associated with CRC. Total cfDNA was extracted, partitioned based on methylation level, and analyzed. Data were then filtered using a variant classifier to differentiate tumor- from non-tumor-derived alterations without a priori knowledge of tissue or germline sequencing results. A machine learning model was trained on 111 cfDNA samples from 38 late stage and 10 early stage CRC pts and 63 age-matched cancer-free controls. For the independent test set, plasma samples (4-5mL) were collected from 72 pts with stage I-IV CRC prior to and 4 weeks after (N = 50, total of 122 samples) surgical resection. 35 age-matched cancer-free controls were similarly analyzed in the test set. Results: Of the 72 pts, 62.5% were male, and median age at CRC diagnosis was 61.5 years (range 36-85). Stage distribution was 52.8% stage I/II, 40.3% stage III, and 6.9% stage IV. In the 50 pts with post-surgical samples, clinical follow-up was available for 49 (median post-surgery follow-up: 314 days; range 15-472). Utilizing this assay, pre-surgery ctDNA detection rate was 94% (68/72); 97% in stage I/II, 90% in stage III, and 100% in stage IV. Epigenomic analysis significantly enhanced ctDNA detection relative to somatic mutational analysis alone (94% vs. 56%; p<0.0001). Specificity in age-matched cancer-free controls was 94%. Discussion: Utilizing a plasma-only sequencing assay incorporating somatic genomic variant detection, epigenomic analysis, and a bioinformatic classifier to filter non-tumor derived variants, ctDNA detection rate in early stage CRC (I-III) is 94% (63/67; 95% confidence interval 86%;98%) with 94% specificity, far outperforming the detection rate of somatic sequence variant detection alone. Clinical follow-up is ongoing to evaluate post-surgery ctDNA detection rate and disease recurrence. These results have significant implications for the clinical utility of ctDNA in early stage cancer management. Citation Format: Seung-Tae Kim, Victoria M. Raymond, Joon Oh Park, Elena Zotenko, Young Suk Park, Matthew Schultz, Won Ki Kang, Oscar Westesson, Hee-Cheol Kim, Yupeng He, Justin I. Odegaard, Stefanie A. Mortimer, William J. Greenleaf, Ariel Jaimovich, Jeeyun Lee, AmirAli Talasaz. Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 916.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
大模型的应助被WX采纳,获得10
1秒前
leclerc发布了新的文献求助10
1秒前
CC完成签到,获得积分10
1秒前
等璃子发布了新的文献求助10
2秒前
3秒前
3秒前
哈哈发布了新的文献求助10
4秒前
vv发布了新的文献求助10
4秒前
6秒前
su完成签到 ,获得积分10
6秒前
隐形曼青的应助被Page_Page采纳,获得30
7秒前
科研狗完成签到,获得积分10
8秒前
七七完成签到,获得积分10
8秒前
8秒前
朱海兰发布了新的文献求助10
9秒前
10秒前
7766发布了新的文献求助30
10秒前
Owen的应助被科研通管家采纳,获得10
10秒前
10秒前
田様的应助被科研通管家采纳,获得10
10秒前
wheat的应助被科研通管家采纳,获得10
10秒前
小马甲的应助被科研通管家采纳,获得10
11秒前
微风发布了新的文献求助10
11秒前
科研狗发布了新的文献求助10
12秒前
怕黑凤妖完成签到 ,获得积分10
12秒前
Hase发布了新的文献求助30
13秒前
激情的冰绿完成签到 ,获得积分10
13秒前
小旋风完成签到,获得积分10
15秒前
15秒前
15秒前
17秒前
xc完成签到 ,获得积分10
18秒前
罗斌奇发布了新的文献求助20
18秒前
强健的寻云完成签到 ,获得积分10
19秒前
唯唯完成签到 ,获得积分10
21秒前
求求毕业发布了新的文献求助10
21秒前
李博文发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165423
求助须知:如何正确求助?哪些是违规求助? 9559005
关于积分的说明 21748579
捐赠科研通 7756086
什么是DOI,文献DOI怎么找? 3428919
关于科研通互助平台的介绍 2553193
邀请新用户注册赠送积分活动 2473473